School of Medicine

Showing 1-6 of 6 Results

  • Nicholas Leeper

    Nicholas Leeper

    Professor of Surgery (Vascular Surgery) and of Medicine (Cardiovascular)
    On Partial Leave from 01/16/2024 To 01/15/2025

    • Contact Info
      • 300 Pasteur Drive, Alway M103B
      • Stanford, California 94305-5642
      Mail Code: 5639
  • Jin Billy Li

    Jin Billy Li

    Professor of Genetics
    On Partial Leave from 07/16/2024 To 11/15/2024

    Current Research and Scholarly InterestsThe Li Lab is primarily interested in RNA editing mediated by ADAR enzymes. We co-discovered that the major function of RNA editing is to label endogenous dsRNAs as "self" to avoid being recognized as "non-self" by MDA5, a host innate immune dsRNA sensor, leading us to pursue therapeutic applications in cancer, autoimmune diseases, and viral infection. The other major direction of the lab is to develop technologies to harness endogenous ADAR enzymes for site-specific transcriptome engineering.

  • Jan Liphardt

    Jan Liphardt

    Associate Professor of Bioengineering

  • Joseph (Joe) Lipsick

    Joseph (Joe) Lipsick

    Professor of Pathology and of Genetics

    Current Research and Scholarly InterestsFunction and evolution of the Myb oncogene family; function and evolution of E2F transcriptional regulators and RB tumor suppressors; epigenetic regulation of chromatin and chromosomes; cancer genetics.

    • Contact Info
      • Lane L217
      • School of Medicine
      • 300 Pasteur Drive
      • Stanford, California 94305-5324
      Mail Code: 5324
      lipsick@stanford.edu
    • Other Names:
      Joe Lipsick
  • Kyle Loh

    Kyle Loh

    Assistant Professor of Developmental Biology (Stem Cell)

    BioHow the richly varied cell-types in the human body arise from one embryonic cell is a biological marvel and mystery. We have mapped how human embryonic stem cells develop into over twenty different human cell-types. This roadmap allowed us to generate enriched populations of human liver, bone, heart and blood vessel cells in a Petri dish from embryonic stem cells. Each of these human cells could regenerate their cognate tissue upon injection into respective mouse models, with relevance to regenerative medicine. In addition to developmental and stem cell biology, we have an emerging interest in exploring deadly biosafety level 4 viruses together with our collaborators.

    Kyle attended the County College of Morris and Rutgers, and received his Ph.D. from Stanford (working with Irving Weissman), with fellowships from the Hertz Foundation, National Science Foundation and Davidson Institute for Talent Development. He then continued as a Siebel Investigator, and later, as an Assistant Professor and The Anthony DiGenova Endowed Faculty Scholar at Stanford, where he is jointly appointed in the Department of Developmental Biology and Institute for Stem Cell Biology & Regenerative Medicine. Kyle is a Packard Fellow, Pew Scholar, Human Frontier Science Program Young Investigator and Baxter Foundation Faculty Scholar, and his research has been recognized by the NIH Director's Early Independence Award, Forbes 30 Under 30, Harold Weintraub Graduate Award, Hertz Foundation Thesis Prize and A*STAR Investigatorship.

    • Contact Info
      • 265 Campus Dr Rm G3120B
      • Lokey Stem Cell Building
      • Stanford, California 94305-5101
      Mail Code: 5463
      kyleloh@stanford.edu
  • Sydney X. Lu

    Sydney X. Lu

    Assistant Professor of Medicine (Hematology)

    BioSydney Lu is a hematologist and medical oncologist in the Division of Hematology, Department of Medicine, studying novel therapeutics for challenging cancers and immune disorders.
    Sydney's research career started with graduate studies in the laboratory of Dr. Marcel van den Brink at Memorial Sloan Kettering Cancer Center (MSKCC) studying the biology of pathologic donor T cells during graft-versus-host-disease and beneficial T cells mediating graft-versus-tumor effects after allogeneic bone marrow transplant, as well as the role of the thymus in regenerating healthy and protective donor-derived T cells post-transplant.
    The direct relevance of these cellular therapies and their immediate translational applicability to patients inspired him to attend medical school at Stanford and further training in hematology and medical oncology at Memorial Sloan Kettering. There, as a fellow and junior faculty member, he studied disordered RNA splicing in cancer in the laboratory of Dr. Omar Abdel-Wahab, with the goal of developing novel drugs targeting RNA splicing. This work has led to observations that targeted degradation of the RNA binding protein RBM39 may be a feasible therapeutic for the treatment of myeloid cancers bearing RNA splicing factor mutations and that pharmacologic RNA splicing inhibition can generate MHC I-presented peptide neoantigens which are exploitable for immunotherapy in model systems.

    Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
    1) normal and pathologic immunity and immunotherapy
    2) cancer biology
    3) normal and malignant hematopoiesis